spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  hypercalcemia 

 HSMN NewsFeed - 24 Feb 2021
Clarus Therapeutics Appoints Richard 'Ric' Peterson as Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 25 Jan 2021
Eiger BioPharmaceuticals Announces U.S. Commercial Availability of Zokinvy(TM) (lonafarnib), the First and Only Treatment Approved for Progeria and Processing-Deficient Progeroid Laminopathies
Biopharmaceuticals Product Launch
 HSMN NewsFeed - 25 Nov 2020
Eiger BioPharmaceuticals Announces FDA Approval of Zokinvy(TM) (lonafarnib): The First Treatment for Hutchinson-Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies
Biopharmaceuticals FDA
 HSMN NewsFeed - 1 Aug 2019
Nektar Therapeutics and Bristol-Myers Squibb Announce U.S. FDA Breakthrough Therapy Designation for Bempegaldesleukin (NKTR-214) in Combination with Opdivo(R) (nivolumab) for the Treatment of Patients with Untreated Advanced Melanoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 May 2019
FDA Approves SORILUX(R) for Adolescent Plaque Psoriasis
Biopharmaceuticals Dermatology FDA
 HSMN NewsFeed - 23 Feb 2018
Amgen Receives Positive Opinion Expanding Use Of XGEVA(R) (denosumab) To Cover Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma In Europe
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 5 Jan 2018
FDA Approves XGEVA(R) (denosumab) For The Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 11 Sep 2017
Advicenne Announces Positive Pivotal Phase III Clinical Data for ADV7103 in Adults and Children Suffering from distal Renal Tubular Acidosis (dRTA)
Biopharmaceuticals
 HSMN NewsFeed - 19 Jun 2017
FDA Accepts Amgen's Supplemental Biologics License Application To Expand Indication For XGEVA(R) (denosumab) To Include Multiple Myeloma Patients
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 30 May 2017
Array BioPharma and Bristol-Myers Squibb Announce Strategic Collaboration
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Apr 2017
FDA Approves Radius Health’s TYMLOS(TM) (abaloparatide), a Bone Building Agent for the Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture
Biopharmaceuticals FDA
 HSMN NewsFeed - 8 Feb 2017
FDA Approves Amgen's Parsabiv(TM) (Etelcalcetide), First New Treatment In More Than A Decade For Secondary Hyperparathyroidism In Adult Patients On Hemodialysis
Biopharmaceuticals Endocrinology FDA
 HSMN NewsFeed - 20 Jan 2017
Bristol-Myers Squibb Provides Regulatory Update in First-line Lung Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 11 Jan 2017
Study Results Published in the Journal of the American Medical Association Show Amgen's Parsabiv(TM) (Etelcalcetide) Significantly Reduced Serum Parathyroid Hormone in Adults With Secondary Hyperparathyroidism on Hemodialysis
Biopharmaceuticals
 HSMN NewsFeed - 11 Nov 2016
Bristol-Myers Squibb’s Opdivo(R) (nivolumab) is the First Immuno-Oncology Treatment to Receive FDA Approval Based on Overall Survival in Head and Neck Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 14 Oct 2016
Bristol-Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) for the Treatment of Adult Patients With Relapsed or Refractory Classical Hodgkin Lymphoma After Autologous Stem Cell Transplant and Treatment With Brentuximab Vedotin
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 24 Nov 2015
European Commission Approves Reconciliation of Indications for nivolumab Under the Opdivo(R) European Marketing Authorization Application
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 1 Oct 2015
Bristol-Myers Squibb Receives Approval from the U.S. Food and Drug Administration for the Opdivo (nivolumab) + Yervoy (ipilimumab) Regimen in BRAF V600 Wild-Type Unresectable or Metastatic Melanoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 24 Apr 2015
Bristol-Myers Squibb Receives Positive CHMP Opinion in the European Union for Opdivo (nivolumab) for the Treatment of Advanced Melanoma in Both First-Line and Previously Treated Patients
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 31 May 2013
Oral Anti-Cancer Therapy Pomalidomide Celgene Receives Positive CHMP Opinion as Treatment for Patients with Relapsed and Refractory Multiple Myeloma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 24 Apr 2012
Genta Appoints Dr. Brian Leyland-Jones and Richard J. Moran to Its Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 15 Jul 2011
XGEVA(R) (Denosumab) Granted Marketing Authorization in the European Union
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 1 Nov 2010
Ortho Clinical Diagnostics Receives FDA Clearance for Intact Parathyroid Hormone Assay
Diagnostics FDA
 HSMN NewsFeed - 6 Apr 2010
Genta's Tesetaxel Granted Fast Track Designation by FDA for Advanced Gastric Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 10 Dec 2009
Data Presented at San Antonio Breast Cancer Symposium Demonstrate Treatment with Denosumab is Superior to the Standard of Care
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 Oct 2009
Genta Announces Top-Line Results of AGENDA Phase 3 Trial of Genasense(R) in Patients with Advanced Melanoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Sep 2009
Denosumab Demonstrates Superiority Over Zometa(R) in Delay of Complications Due to Bone Metastases in Advanced Breast Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 21 Sep 2009
Phase 3 Trial Shows Denosumab Delayed Skeletal Related Events in Advanced Cancer Patients With Bone Metastases
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Mar 2009
FDA Appeal Decision Indicates that Genasense(R) Approval in Chronic Lymphocytic Leukemia Will Require Additional Confirmatory Trial
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 11 Feb 2009
Genta Submits Randomized Study of Tesetaxel in Patients with Advanced Gastric Cancer to FDA for Special Protocol Assessment
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 30 Jun 2008
Odanacatib, an Investigational Cathepsin K Inhibitor, Reduced Markers of Bone Turnover in Women with Breast Cancer and Bone Metastases
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 May 2008
Long-Term Followup in Phase 3 CLL Trial Shows Genasense(R) is Associated with Significantly Increased Survival in All Responders
Biopharmaceuticals Oncology
 HSMN NewsFeed - 27 May 2008
Odanacatib, Merck's Investigational Cathepsin K Inhibitor, Reduced Markers of Bone Turnover in Women with Breast Cancer and Bone Metastases
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Apr 2008
Genta Restructures Operations to Focus on Priority Initiatives
Biopharmaceuticals
 HSMN NewsFeed - 19 Mar 2008
Samaritan Pharmaceuticals Acquires Commercialization Rights to Market and Distribute Abiogen's Cancer Drug Abioklad in Greece, Cyprus and Turkey
Biopharmaceuticals Distribution
 HSMN NewsFeed - 17 Mar 2008
FDA Indicates That Genasense(R) Approval in Chronic Lymphocytic Leukemia Will Require Additional Confirmatory Data
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Mar 2008
Genta Announces Licensing Agreement for Worldwide Development and Commercialization of a Leading Oral Taxane, Tesetaxel
Biopharmaceuticals Licensing Oncology
 HSMN NewsFeed - 22 Feb 2008
Genta Announces Senior Management Changes
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 Nov 2007
FORTEO(R) Increased Spine Bone Mineral Density in Patients with Glucocorticoid-Induced Osteoporosis
Biopharmaceuticals
 HSMN NewsFeed - 8 Nov 2007
Genasense(R) Triple Combination Therapy in Advanced Melanoma Presented at Chemotherapy Foundation Symposium
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 Oct 2007
Genta Announces Resignation of Dr. Betsy McCaughey from Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 17 Sep 2007
A Major Pharmaceutical Company Has Taken an Exclusive Option To BA058, a Compound Licensed by Ipsen to Radius in 2005
Biopharmaceuticals Licensing
 HSMN NewsFeed - 21 Aug 2007
Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Aug 2007
Genta Announces Launch of Genasense(R) Named-Patient/Compassionate Use Program
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Aug 2007
Genta and Emisphere Technologies File IND with FDA for Oral Drug to Treat Bone Disease
Biopharmaceuticals Drug Delivery FDA
 HSMN NewsFeed - 13 Jun 2007
Bradley Pharmaceuticals Announces Launch of Elestrin(TM)
Biopharmaceuticals
 HSMN NewsFeed - 4 Jun 2007
Phase 2 Clinical Results of Ganite(R) Plus Standard Therapy in Patients with Relapsed/Refractory Lymphoma Presented at ASCO
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 May 2007
CollaGenex Pharmaceuticals and QuatRx Pharmaceuticals Announce Agreement for the Development and Commercialization of Becocalcidiol
Biopharmaceuticals Dermatology Licensing
 HSMN NewsFeed - 27 Apr 2007
CHMP Adopts Negative Opinion on Genasense(R) Application in Melanoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 18 Apr 2007
Genta Announces New Phase 3 Trial of Genasense(R) in Patients with Advanced Melanoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Apr 2007
Genta Appeals FDA Decision on Genasense(R) in CLL
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 7 Mar 2007
Genta and IDIS Announce Global Ex-U.S. Agreement for Named Patient/Compassionate Use Distribution of Ganite(R) and Genasense(R)
Biopharmaceuticals
 HSMN NewsFeed - 23 Feb 2007
Phase 2 Results of Genasense(R) Plus Chemotherapy in Advanced Prostate Cancer Reported at Cancer Conference
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Feb 2007
Genta Cites Publication of Study Showing Improved Outcomes in CLL Patients Treated With Genasense(R) Plus Chemotherapy
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Feb 2007
Genta Announces the Company Will Appeal FDA Action on New Drug Application of Genasense(R) in Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Feb 2007
Genta Completes Response to EMEA List of Outstanding Issues for Genasense(R) Marketing Authorization Application in Melanoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 25 Jan 2007
European Association of Nuclear Medicine Journal Article Reports New Data Regarding Administration of QUADRAMET(R) with Chemotherapy in Hormone Refractory Prostate Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Dec 2006
Genta Restructures Operations to Focus on Future Initiatives
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Dec 2006
American Cancer Society Journal Article Reports New Data Regarding Repeated Administration of QUADRAMET(R)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Dec 2006
Genta Receives Non-Approvable Notice for Application of Genasense(R) in Patients With Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 8 Dec 2006
Genta Provides Update on Analysis of Phase 3 Trial of Genasense(R) in Older Patients with Acute Myelogenous Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Dec 2006
Publications Feature VELCADE(R) (Bortezomib) for Injection Strength In Hematological Cancers
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 Nov 2006
Genta Initiates Pilot Clinical Trial of Genasense(R) Plus Abraxane(R) and Temodar(R) as First-Line Therapy for Patients with Advanced Melanoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Nov 2006
Nabi Biopharmaceuticals Closes Sale of PhosLo(R) to Fresenius Medical Care
Biopharmaceuticals
 HSMN NewsFeed - 31 Oct 2006
Patient Accrual Completed into Phase 3 Trial of Genasense(R) in Patients with Acute Myeloid Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 Oct 2006
Millennium and Ortho Biotech Enter into U.S. Co-Promotion Agreement for VELCADE(R)(bortezomib) for Injection
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Oct 2006
Genasense(R) Receives Orphan Drug Designation in Australia for Patients With Advanced Melanoma
Biopharmacetuicals Oncology Regulatory
 HSMN NewsFeed - 16 Oct 2006
Nabi Biopharmaceuticals Announces Positive Results From PhosLo(R) EPICK Study
Biopharmaceuticals
 HSMN NewsFeed - 12 Oct 2006
Nabi Biopharmaceuticals Signs Definitive Agreement To Sell PhosLo(R) To Fresenius Medical Care
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 6 Oct 2006
Journal of Clinical Oncology Publishes Final Study Results of VELCADE(R) (Bortezomib) for Injection in Relapsed Mantle Cell Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Oct 2006
Genta Receives Special Protocol Assessment from FDA for Randomized Trial of Genasense(R) Plus Chemotherapy in Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 26 Sep 2006
Millennium Agrees to Acquire AnorMED, Adding Phase III Oncology Product with Planned Near Term Launch Date
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 19 Sep 2006
Cancer Patients Show Reduced Pain and Lower Analgesic Consumption Following Treatment with QUADRAMET(R)
Biopharmaceuticals Onoclogy
 HSMN NewsFeed - 15 Sep 2006
Final Report of Genasense Phase 3 Trial in Melanoma Published in Journal of Clinical Oncology
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Aug 2006
Genta Revises Notice of Special Protocol Assessment for Confirmatory Trial of Genasense(R) Plus Chemotherapy in Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 9 Aug 2006
FDA Grants Priority Review to VELCADE(R) (Bortezomib) for Injection for Treatment of Relapsed Mantle Cell Lymphoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 27 Jul 2006
Genta Announces FDA's Oncology Drug Advisory Committee Will Review Genasense(R) as Treatment for Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 26 Jul 2006
Cytogen Announces Initiation of Phase III Study Involving QUADRAMET(R)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 Jul 2006
Genta Receives Special Protocol Assessment from FDA for Confirmatory Trial of Genasense(R) Plus Chemotherapy in Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 26 Jul 2006
Cytogen Announces Publication of Peer-Reviewed Journal Article on QUADRAMET(R)
Biopharmaceuticals
 HSMN NewsFeed - 18 Jul 2006
Nabi Biopharmaceuticals Releases New Data which Demonstrate Superior Serum Phosphorus Control with PhosLo(R) (calcium acetate) over Sevelamer
Biopharmaceuticals
 HSMN NewsFeed - 16 Jul 2006
Amgen Announces EVOLVE Trial(TM) To Investigate Impact of Sensipar(R)/Mimpara(R) (cinacalcet HCl) on Mortality and Cardiovascular Morbidity in Secondary Hyperparathyroidism Patients With Chronic Kidney Disease Receiving Dialysis
Biopharmaceuticals
 HSMN NewsFeed - 21 Jun 2006
VELCADE(R) (Bortezomib) for Injection Showed Unprecedented Results In Newly Diagnosed Multiple Myeloma Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Apr 2006
Millennium and Johnson & Johnson Pharmaceutical Research and Development Initiate Phase III Clinical Trial with VELCADE(R) (bortezomib) for Injection in Follicular Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Apr 2006
Novacea Initiates Pivotal Phase 3 Clinical Study of DN-101 in Men With Advanced Prostate Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 Mar 2006
Genta and Emisphere Technologies Enter into Exclusive Worldwide Licensing Agreement for Development of an Oral Gallium Compound
Biopharmaceuticals Licensing
 HSMN NewsFeed - 10 Mar 2006
NPS Receives Approvable Letter for PREOS NDA
Biopharmaceuticals FDA
 HSMN NewsFeed - 6 Mar 2006
Millennium and Johnson & Johnson Pharmaceutical Research & Development Initiate Randomized Phase II Trial of VELCADE(R) (Bortezomib) for Injection in Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Mar 2006
Randomized Trial Shows Ganite(R) Effective When Compared with a Leading Bisphosphonate in Patients with Cancer-Related Hypercalcemia
Biopharmaceuticals
 HSMN NewsFeed - 1 Mar 2006
Genasense(R) New Drug Application Accepted for Review by FDA
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 15 Feb 2006
Keryx Biopharmaceuticals Announces Expansion of Renal Franchise With the In-Licensing of Zerenex(TM), a Novel Phosphate Binder
Biopharmaceuticals Licensing
 HSMN NewsFeed - 2 Feb 2006
Analysis of Genasense(R) Trial Confirms Major Efficacy Variables in Patients with Advanced Melanoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Feb 2006
Genasense(R) Marketing Authorization Application in Melanoma Accepted for Review by European Regulatory Agency
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 25 Jan 2006
Millennium Announces Appointments of Executive Vice President of Commercial Operations, Vice President of Finance and Several Key Promotions
Biopharmaceuticals Personnel
 HSMN NewsFeed - 24 Jan 2006
Subcutaneous Genasense(R) Trial Initiated in Patients with Solid Tumors
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Jan 2006
Genta Appoints Dr. Per Lindell as Vice President of Business Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 17 Jan 2006
Genta Appoints Seasoned Pharma Executive, Lloyd Sanders, as Vice-President for Sales and Marketing
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 3 Jan 2006
Genta Completes Marketing Authorization Application to EMEA for Approval of Genasense(R) plus Chemotherapy for Patients with Advanced Melanoma
Biopharmaceuticals Oncology Regulatory
Return to NewsFeed  

 Additional items found! 94

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 94 additional stories matching:
hypercalcemia
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.